Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ASMB

Assembly Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ASMB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 10:12 UTC.

What Assembly Biosciences, Inc. does

Abivax is a biotechnology company developing antiviral therapeutics for serious viral diseases. The company's clinical pipeline includes long-acting helicase-primase inhibitors for recurrent genital herpes (which Gilead licensed in December 2025), an oral hepatitis delta virus entry inhibitor, a hepatitis B virus capsid assembly modulator, and an oral broad-spectrum antiviral for transplant-related herpesviruses undergoing regulatory filing-enabling studies. The company reported positive clinical data across multiple programs in 2025 and continues research against additional viral targets.

Summarized from Assembly Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-2.96%

Revenue, margins & earnings

FY2021: net loss $130M on revenue $6M$6MFY2021FY2023: net loss $61M on revenue $7M$7MFY2023FY2024: net loss $40M on revenue $29M$29MFY2024FY2025: net loss $6M on revenue $72M$72MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-18
Most recent filed transactions — June 2026:
  • 2026-06-18PFO and PAOSale-29$674
  • 2026-06-05DirectorStock Option (right to buy)Award8,000—
  • 2026-06-05DirectorStock Option (right to buy)Award8,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Assembly Biosciences, Inc. do?

Abivax is a biotechnology company developing antiviral therapeutics for serious viral diseases.

When did ASMB last file with the SEC?

Assembly Biosciences, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:12 UTC. This page is also available as JSON at /api/data?ticker=ASMB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ASMB and 5,000+ tickers.

Create a free account — keep ASMB
For your agent
GET /api/data?ticker=ASMB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt